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ABSTRACT
Background
Observational studies indicate that physical activity (PA)
is strongly associated with improved disease outcomes
in colon cancer survivors, but a randomized controlled
trial is needed to determine whether the association is
causal and whether new policies to promote exercise
are justified.
Purpose
The CO.21 Colon Health and Life-Long Exercise
Change (CHALLENGE) trial undertaken by the National
Cancer Institute of Canada Clinical Trials Group (NCIC
CTG) is designed to determine the effects of a struc-
tured PA intervention on outcomes for survivors of high-
risk stage II or III colon cancer who have completed
adjuvant therapy within the previous 2–6 months.
Methods
Trial participants (n = 962) will be stratified by centre,
disease stage, body mass index, and performance sta-
tus, and will be randomly assigned to a structured PA
intervention or to general health education materials.
The PA intervention will consist of a behavioural sup-
port program and supervised PA sessions delivered over
a 3-year period, beginning with regular face-to-face
sessions and tapering to less frequent face-to-face or
telephone sessions. The primary endpoint is disease-
free survival. Important secondary endpoints include
multiple patient-reported outcomes, objective physical
functioning, biologic correlative markers, and an eco-
nomic analysis.
Summary
Cancer survivors and cancer care professionals are
interested in the potential role of PA to improve
multiple disease-related outcomes, but a randomized
controlled trial is needed to provide compelling evi-
dence to justify changes in health care policies and
practice.
KEY WORDS
Behavioural oncology, cancer survivor, disease-free
survival, exercise, lifestyle, physical activity, quality
of life, survivorship
1. INTRODUCTION
Since the 1990s, a 6-month course of adjuvant chemo-
therapy has been the standard of care for patients with
resected high-risk stage II or III colon cancer 1. De-
spite recent advances in adjuvant therapy, a substan-
tial proportion of such patients still experience disease
relapse and premature death 2. Recently published ob-
servational data suggest that physical activity (PA) is
associated with a reduced risk of disease relapse and
premature death in these colon cancer survivors.
In 2006, Meyerhardt et al. 3 reported results of a
prospective observational study of 832 patients with
stage III colon cancer enrolled in a randomized
adjuvant chemotherapy trial and followed for a me-
dian of 3.8 years from trial entry. In that trial, PA was
self-reported approximately 6 months after comple-
tion of chemotherapy and was quantified as weekly
metabolic equivalent task (MET)–hours (for example,
walking briskly is approximately 4.0 METs). Catego-
ries of PA were predefined in terms of these MET–
hours: fewer than 3 (referent), 3–8.9, 9–17.9, 18–26.9,
and more than 27. Analyses adjusted for known prog-
nostic factors, including body mass index (BMI), indi-
cated that higher levels of PA were associated with
superior disease-free (DFS), recurrence-free, and over-
all survival. The 3-year DFS was 75.1% in patients
who exercised for fewer than 18 MET–hours weekly
as compared with 84.5% in patients who exercised
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for more than 18 MET–hours weekly [hazard ratio (HR):
0.57; 95% confidence interval (CI): 0.39 to 0.85].
In a second article, Meyerhardt et al. 4 reported
results of a prospective observational study of 573
women from the Nurses’ Health Study diagnosed with
stages I–III colorectal cancer. Self-reported leisure-time
PA before diagnosis and 1–4 years post-diagnosis was
assessed, and analyses were again adjusted for known
prognostic factors, including BMI. An inverse relation-
ship was observed between the amount of PA post-di-
agnosis and the risk of both colorectal cancer–specific
and overall mortality. Specifically, as compared with
women exercising for fewer than 3 MET–hours weekly,
the risk of colorectal cancer–specific mortality declined
in successive groups performing more exercise: the
HR was 0.92 (95% CI: 0.50 to 1.69) in the 3–8.9 MET–
hours weekly group, 0.57 (95% CI: 0.27 to 1.20) in the
9–17.9 MET–hours weekly group, and 0.39 (95% CI:
0.18 to 0.82) in the more than 18 MET–hours weekly
group. Risk of overall mortality was similarly reduced.
Furthermore, change in PA from pre- to post-diagnosis
was also predictive of outcome. Compared with
women who did not change their PA, women who in-
creased their PA by at least 1 predefined MET cat-
egory—for example, from fewer than 3 MET–hours
to 3–8.9 MET–hours—between their pre-diagnostic and
post-treatment assessments experienced improved
outcomes; women whose exercise levels decreased
by at least 1 predefined MET category had poorer out-
comes. Further analysis of these data suggested that
no additional benefit accrued with an increase in PA
post-diagnosis in women who were already achiev-
ing at least 9 MET–hours weekly before diagnosis (that
is, those who were roughly already meeting current
public health guidelines).
Several plausible biologic mechanisms could ac-
count for an association between PA and colon cancer
outcomes, including metabolic consequences of obes-
ity; decreased gastrointestinal transit time; decreased
levels of insulin, insulin-like growth factors, and pros-
taglandin ratios; lowered bile acid secretion; and al-
tered gut flora 5. Moreover, there is evidence that colon
cancer survivors experience significant declines in PA
during adjuvant therapy 6 and that they report among
the lowest PA participation rates of any cancer survi-
vor group 7, suggesting that, in the current PA levels of
colon cancer survivors, there is considerable room for
improvement from a public health perspective. Finally,
progress has been made in the science of health be-
haviour change over the past decade demonstrating that
PA can, indeed, be increased substantially and main-
tained over extended periods of time with an appropri-
ate behavioural support program 8–10. Together, these
observations suggest that interventions to increase PA
in colon cancer survivors may improve disease out-
comes, that associated correlative biologic studies may
provide insights into the mechanisms of colon cancer
pathogenesis, and that sufficient understanding exists
to implement an effective intervention.
Despite the highly suggestive observational find-
ings, a randomized controlled trial (RCT) is needed to
establish unequivocally the causal nature of this asso-
ciation and to inform policies for health care delivery.
The primary objective of the Colon Health and Life-
Long Exercise Change (CHALLENGE) trial CO.21 be-
ing undertaken by the National Cancer Institute of
Canada Clinical Trials Group (NCIC CTG) is to deter-
mine the effects of a 3-year structured PA intervention
on DFS in survivors of high-risk stage II or III colon
cancer who have completed adjuvant chemotherapy in
the preceding 2–6 months and who are insufficiently
active. Secondary objectives are to
￿ determine the effects of the PA intervention on
important secondary endpoints including overall
survival, multiple patient-reported outcomes
(PROs), and objective physical functioning.
￿ identify the determinants of long-term PA adher-
ence in the intervention arm.
￿ explore the associations between selected molecu-
lar markers and study endpoint measures.
￿ provide an economic evaluation of the PA inter-
vention.
We hypothesize that colon cancer survivors randomized
to the PA intervention arm will experience improve-
ments in DFS, PROs, and objective physical function-
ing as compared with survivors allocated to general
health education.
2. METHODS
2.1 Study Design and Participants
We will be conducting a multinational, multicentre,
phase III trial with randomization to a PA intervention
versus general health education materials. This study
will be led by the NCIC CTG and will include collabora-
tion with the Australasian Gastro-Intestinal Trials
Group. Figure 1 presents the anticipated flow of par-
ticipants through the trial. Medically-fit survivors of
high-risk stage II or III colon cancer who have received
their last dose of adjuvant chemotherapy within the
preceding 60–180 days will be recruited. This group
has been identified as being at high risk for disease re-
currence or death, being most likely to adhere to the
intervention, and being individuals for whom the PA in-
tervention is safe. Table I details the eligibility criteria.
Pre-registration evaluations will focus on current
PA involvement and medical eligibility for study par-
ticipation. Patients who are already meeting current
public health guidelines for PA (150 minutes or more
of moderate-to-vigorous or 75 minutes or more of vig-
orous PA weekly), as estimated for the month before
registration using the Leisure Time Exercise Question-
naire, will be ineligible. Consenting patients will be
registered and will then undergo submaximal exercise
testing to ensure that they are able to exercise safely atTHE CHALLENGE TRIAL
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a moderate-to-vigorous intensity. Provided that 2 stages
of the treadmill test are completed with acceptable
heart rate and blood pressure responses, patients will
then complete the remaining baseline investigations,
including a physical functioning test, anthropometric
testing, blood collection for correlative studies, PROs,
PA behaviour and determinants, health utility, and a
health economics work productivity and activity im-
pairment questionnaire (WPAI). Patients will then be
stratified by centre, disease stage (high-risk II vs. III),
BMI (≤27.5 vs. >27.5), and Eastern Cooperative Oncol-
ogy Group performance status (0 vs. 1), and will be
randomized to receive the PA intervention program (in-
tervention arm) or general health education materials
(comparison arm).
2.2 Physical Activity Intervention
Participants in both arms will be provided with general
health education materials including information about
nutrition and PA. Participants in both groups will also
receive follow-up care at the participating cancer cen-
tre, including regular physician visits, imaging, blood
work, and colonoscopy. Participants assigned to the PA
intervention will receive a structured 3-year PA pro-
gram delivered by a local PA consultant (PAC). The
goal for the PA intervention group is to increase rec-
reational PA from baseline by at least 10 MET–hours
weekly to a maximum of 27 MET–hours weekly. The
10 MET–hours weekly is roughly equivalent to the
current public health guidelines of about 2.5 hours (for
example, 5 days of 30 minutes daily) of moderate-in-
tensity PA weekly, such as brisk walking (4 METs), or
1.25 hours (for example, 3 days of 25 minutes daily) of
vigorous-intensity PA weekly such as jogging (8 METs).
At the end of 6 months, a decision to encourage par-
ticipants to increase PA by more than 10 MET–hours
weekly will be determined and will depend on their
adaptation to the initial goal of an increase of 10 MET–
hours weekly. Patients will not be encouraged to in-
crease their PA beyond 27 MET–hours weekly, which
is equivalent to about 1 hour daily of brisk walking for
7 days each week or 1 hour daily of jogging for 3.5
days each week.
Achieving an increase in PA from baseline of at
least 10 MET–hours weekly will require a significant
amount of behaviour support. Participants in the in-
tervention arm will therefore receive an intensive
behaviour support program based on the Theory of
Planned Behaviour 11 and modelled after the successful
behavioural change program in the Diabetes Preven-
tion Program 10 and the Look AHEAD trial 8. The PA
intervention will be delivered in 3 distinct phases and
will consist of behaviour support sessions and super-
vised PA sessions (Table II). The intervention will in-
clude a personalized PA prescription that accounts for
the individual’s baseline fitness test results, PA history,
performance status, personal preferences, and indi-
vidual barriers to activity.
FIGURE 1   Flow of participants through the Colon Health and Life-Long Exercise Change (CHALLENGE) trial.COURNEYA et al.
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2.3 Behaviour Support Sessions
Behaviour support sessions will include training in be-
havioural strategies to promote the adoption and long-
term maintenance of PA. Key behavioural strategies will
include an emphasis on the unique benefits of PA for
colon cancer survivors; strategies for making PA enjoy-
able, for overcoming barriers, for securing social sup-
port from family and friends, and for identifying
environmental opportunities; and time management, self-
monitoring, goal setting, planning, stimulus control, and
self-reinforcement. At the core of the behavioural inter-
vention will be a PA guidebook that will contain topics
and materials that the PACs can use to reinforce and
expand on during counselling sessions. The guidebook,
called Step Up to the Challenge!, will be distributed to
each PA intervention participant as an ongoing resource.
It is modeled after a guidebook originally developed for
breast cancer survivors and has been shown to be effec-
tive for increasing motivation, PA, and quality of life in
breast cancer survivors 12–14. Throughout all phases of
the study, PACs are able to provide additional behaviour
support sessions if they determine that a patient is expe-
riencing difficulty with adherence.
Advanced behavioural strategies will be consid-
ered for patients who have significant struggles in adopt-
ing or maintaining PA despite continued support from
the PAC. A behavioural toolbox will assist in overcom-
ing barriers to PA, many of which will likely be related
to issues of opportunity to perform exercise in the win-
ter. The primary approach will be to have a facility
available free of charge year round at each centre. All
TABLE I Inclusion and exclusion criteria for the CHALLENGE trial
Inclusion criteria for registration
￿ Completely resected, histologically documented, high-risk stage II or III adenocarcinoma of the colon
￿ Adjuvant chemotherapy treatment for colon cancer with a 5-fluorouracil–based regimen given with an intent to provide 24 weeks of
treatment (actual treatment may be less than 24 weeks, and patients must have received a minimum of 1 treatment cycle)
￿ Chemotherapy completed 60–180 days before registration
￿ 18 Years of age or older
￿ Medically suitable for exercise testing and for participation in physical activity (by revised Physical Activity Readiness Question
naire and investigator opinion)
￿ Eastern Cooperative Oncology Group performance status of 0 or 1
￿ Adequate hematologic, renal, and hepatic function
￿ No evidence of metastatic or locally-recurrent colon cancer [by chest radiography or computed tomography (CT), and CT of
abdomen and pelvis]
￿ Current physical activity levels that do not meet the current recommended guidelines (150 minutes or more of moderate-to-
vigorous or 75 minutes or more of vigorous physical activity weekly) calculated using the Godin–Shephard Leisure Time Exercise
Questionnaire
￿ Ability and willingness to effectively communicate with the physical activity consultant
￿ Ability and willingness to complete all questionnaires involved in study (provided in English and French)
￿ Informed consent granted
￿ Accessibility for treatment and follow-up
Exclusion criteria for registration
￿ Significant comorbid conditions precluding participation in a physical activity program
￿ Locoregional or distant metastatic disease
￿ Unlikely to participate in a physical activity program (as assessed by the investigator)
￿ History of other malignancies, except adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix or
other solid tumours; Hodgkin lymphoma or non-Hodgkin lymphoma curatively treated, with no evidence of disease for more than 5
years
￿ Treatment with a beta-blocker and unwillingness or inability to discontinue that medication for 48 hours before each required
exercise test, or any other medications deemed by the investigator to be likely to preclude participation in a physical activity
program
￿ Current treatment with additional chemotherapy or radiation
￿ Inability to complete the baseline exercise test
￿ Current pregnancy or plans to become pregnant within the next 3 years
Inclusion criteria for randomization
￿ Completion of at least 2 stages of the submaximal exercise test with acceptable heart rate and blood pressure response
￿ Completion of anthropometric testing, a Senior’s Fitness Test, Patient Reported Outcomes, Health Economics, and Physical
Activity Behaviour and Adherence questionnaires (including the Total Physical Activity Questionnaire to calculate baseline weekly
metabolic equivalent task–hours)
￿ Mandatory blood samples for correlative studies
￿ Fasting glucose sample
￿ Protocol intervention to begin within 14 days of patient randomizationTHE CHALLENGE TRIAL
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patients will also be provided with pedometers to mo-
tivate them and to help them track their PA.
2.4 Supervised Physical Activity Sessions
In addition to counselling sessions focusing on behav-
iour support, patients will also receive supervised PA
sessions. These sessions will be combined with be-
haviour support sessions and will also occur independ-
ently. Their focus will be to teach proper PA technique
and how to monitor intensity and to progress PA safely
and effectively. In the first 6 months, these mandatory
sessions will be supervised by the PAC. Thereafter,
supervision is strongly recommended. The supervision
may be 1:1 with the PAC or in a group format. Throughout
all phases of the study, PACs will be able to provide
additional supervised PA sessions if they determine that
a patient is experiencing difficulties with adherence.
Patients will be provided free access to a fitness facil-
ity at times outside of their supervised PA sessions.
2.5 Primary and Secondary Endpoints
Table III presents the nature and timing of the study
evaluations. The primary endpoint is DFS, because
available data demonstrate that 3-year DFS is highly
correlated with overall survival in patients with resected
colon cancer 15. This endpoint is now accepted for reg-
istration of trials by the U.S. Food and Drug Adminis-
tration. Secondary endpoints will include overall
survival, PROs assessing quality of life [the Short Form
(SF-36) and Functional Assessment of Cancer Therapy,
General subscale], fatigue (Functional Assessment of
Cancer Therapy, Fatigue subscale), sleep quality (Pitts-
burgh Sleep Quality Index), and anxiety and depression
(Hospital Anxiety and Depression Scale), and objec-
tive testing of physical functioning consisting of an-
thropometric measurements, cardiovascular fitness
(submaximal exercise test using the Balke treadmill
protocol 16); and physical functioning (Seniors Fitness
Test 17). Adherence to PA will be assessed at baseline
and every 6–12 months by using a slight modification of
the Past Year Total Physical Activity Questionnaire 18,19.
The Past Year Total Physical Activity Questionnaire
has been shown to have acceptable reliability and va-
lidity for measurement of past-year PA 19. Correlative
biologic markers will include blood measures of insu-
lin, insulin-like growth factors, and selected cytokines.
Finally, an economic evaluation will be performed to
assess cost-effectiveness and cost–utility of the PA
TABLE II   Physical activity program intervention
           Content              Phase
       Baseline to 6 mo.             6–12 mo.         12–36 mo.
Behaviour support sessions a 12 Mandatory face-to-face 12 Mandatory sessions held Mandatory monthly
sessions held biweekly biweekly, with option for sessions, with option for
face-to-face or telephone face-to-face or telephone
delivery delivery
Supervised physical 12 Mandatory sessions 12 Sessions Monthly sessions
activity sessions a,b combined with the recommended; can be recommended; can be
mandatory behaviour combined with the combined with the
support sessions biweekly behaviour monthly behaviour
support sessions for those support sessions for
who choose face-to-face those who choose face-
sessions  to-face sessions
12 Additional supervised
physical activity sessions
on alternate weeks
strongly recommended
Physical activity goal c Gradually increase Individualized (based on Individualized (based on
recreational physical phase I results) to a phase II results) to a
activity by 10 metabolic maximum increase of 20 maximum total of 27 MET–
equivalent task (MET)– MET–hours weekly (to a hours weekly
hours weekly over total of 20–27 MET–hours
baseline (to 10–19 MET– weekly)
hours weekly)
a Physical activity consultants can provide additional behavioural support and supervised physical activity sessions in any phase if
they determine that a patient is experiencing difficulty with adherence.
b Patients will be provided with access to a fitness facility outside of the scheduled sessions; however, no behaviour support or
physical activity supervision will be provided.
c All increases in physical activity refer only to recreational activity metabolic equivalent task (MET)–hours weekly.COURNEYA et al.
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intervention. Patient utilities will be measured using
the SF-6D, which is derived from the SF-36 quality-of-
life measure 20 that has been validated in population
surveys and clinical trials settings. Resource utiliza-
tion and WPAI will be collected prospectively as part
of the economic analysis.
2.6 Statistical Considerations
The analysis will be performed using the intent-to-treat
principle and is powered to detect a HR of 0.75 for DFS
between patients randomized to two treatment arms.
To detect such a HR with a power of 80% and a two-
tailed alpha of 0.05, we will need to observe 380 events
during follow-up. It is anticipated that a total of 962
patients will be randomized over 3 years. To observe
380 events, we assume that the patients in the com-
parison group will have a 3-year DFS of 75% and will
not materially change their PA behaviour from base-
line. It is also assumed that 20% of patients randomized
to the intervention group will not adhere to their PA
program. With these assumptions, it is estimated that,
to observe 380 events among 962 patients randomized,
4.7 years of additional follow-up after the last patient
is randomized will be required, which leads to an ap-
proximate total study duration of 7.7 years. Four in-
terim analyses will be performed: the first analysis will
assess the feasibility of accrual principles, the second
will assess the feasibility of the PA behaviour change,
and the final two will assess for unexpectedly large
magnitudes of benefit or futility.
2.7 Trial Management
The development and oversight of the CO.21 trial is
provided by the Trial Steering Committee, which in-
cludes the study chairs and the Design and Conduct
Committee members; the coordinators for Quality of
Life, Economic Evaluations, and Correlative Sciences
committees; and the NCIC CTG central office physi-
cian coordinator, senior biostatistician, and study co-
ordinator. Because of the complexities of delivering
a lifestyle intervention and because of the uniqueness of
this study, four working groups were established to
provide expertise in protocol development and trial im-
plementation in four key areas: PA, PROs, health eco-
nomics, and correlative studies. Each of these working
groups is chaired by a member of the Trial Steering
Committee with expertise in the respective field. A PA
Working Group will provide oversight to the PA and
behaviour support components of the study, including
monitoring of adherence. This working group is led by
the study chair.
3. DISCUSSION
Colorectal cancer is the third most common cancer
in Canadian men and women and the second leading
cause of cancer-related death 21. There are more than
110,000 colorectal cancer survivors in Canada. This
growing number of survivors has generated interest in
behaviour and lifestyle interventions that might further
improve disease outcomes and quality of life. In colon
cancer, PA has been strongly associated with improved
disease outcomes, and there are plausible biologic
mechanisms for this association. However, the data
published to date have been observational. Moreover,
few colon cancer survivors currently exercise, partly
because of the physical and psychological effects of
their disease and treatments, and partly because of the
lack of guidance and support from cancer care organi-
zations. However, recent progress in behavioural change
suggests that, with appropriate support, such populations
can be motivated to adopt long-term lifestyle changes.
Consequently, all the necessary evidence, rationale, and
justification exist to warrant the conduct of an RCT of
PA and disease outcomes in colon cancer survivors.
Moreover, in the era of molecularly targeted anti-
cancer therapy, funding of new and expensive agents
is becoming increasingly difficult. Should a PA inter-
vention be found to have a significant clinical benefit
in colon cancer patients, this type of intervention could
be a very cost-effective therapy, with the potential for
many other non-cancer-related health benefits. The
magnitude of the associations between PA and disease
outcomes in the observational studies of colon cancer
compares favourably with the benefit observed with
the use of adjuvant chemotherapy, but would likely in-
volve lower toxicity and cost. Importantly, the cost-
effectiveness of this PA intervention will be
prospectively evaluated as part of this clinical trial,
because all interventions are recognized to have a cost
component that needs to be considered when evaluat-
ing the effectiveness of the intervention to reduce the
burden of a disease at a population level.
Positive findings from the CHALLENGE trial would
support a new and additional paradigm to be tested in
patients with other forms of cancer and would enhance
interest in applying these results to test strategies for
cancer prevention. One of the greatest challenges to
implementing PA programs in any population has been
ensuring adequate support and resources to promote
behaviour change with regard to PA. Cancer patients
are, in general, a sedentary but motivated population.
Previous work has suggested good adherence and a
willingness to pursue lifestyle modifications following
a diagnosis of cancer. If this RCT is able to demon-
strate a significant benefit in DFS, that finding would
provide an impetus to patients to participate in PA and
to oncologists and cancer care organizations to pro-
mote PA. It could also potentially lead to changes in
public perception that might influence the policies by
which PA experts are utilized within the health care
system. The CHALLENGE trial will also have an op-
portunity to evaluate the cost-effectiveness of poten-
tial policy recommendations.THE CHALLENGE TRIAL
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TABLE III    Study evaluations
Required investigations              Before Until recurrence or After recurrence or
Reg.   Rand. new primary malignancy new primary malignancy
Every 6 mo. Every 12 mo. Every 12 mo. Every 6 mo. Every 12 mo. Every 12 mo.
(years 1–3) (years 4–5) (years 6–10) (years 1–3) (years 4–5) (years 6–10)
History and physical
Blood pressure + heart rate X
History, physical exam, X X X X X X X
    weight, height
Disease status and X X X X X X X
   overall survival
ECOG performance status X
Exercise screening questionnaire X
Medical Suitability for X
   Exercise questionnaire
Major medical problems X
Concomitant medications X X X X X X X
Hematology
Absolute granulocyte count + X
   hemoglobin + platelets +
   white blood cells
Biochemistry
Liver function tests X
   (bilirubin, alkaline
   phosphatase, AST or ALT)
Creatinine X
Carcinoembryonic antigen X X X
Radiology
Chest radiography or X X X
   computed tomography
Abdomen and pelvis X X X
   computed tomography
Colonoscopy                       Once, 30–48 mo.
                    after randomization
Other                     As clinically indicated to document
      recurrence or new primary malignancy
Fitness testing
Submaximal Exercise Test X Xa
Seniors’ Fitness Test X Xa
Hip and waist circumference X Xa
Other investigations
Serum and plasma X Xb
Fasting glucose X
Adverse events
Adverse event assessments X X X X X X X
Patient-reported outcomes
FACT-F X X X
SF-36 (quality of life) X X X X X
Pittsburgh Sleep Quality Index X X X
Hospital Anxiety and X X X
   Depression Scale
Physical activity behaviour
Total Physical Activity Questionnaire X X X
Social-Cognitive Determinants X X
   of Exercise
Health economics
Resource Utilization Assessment X X X X
Work Place Activity and X X X X X
   Impairment Questionnaire
30-Day Resource Use Diary Xc XX X
a   At 6, 12, 24, and 36 months.
b   At 12, 24, and 36 months.
c   Including the first month of the intervention period.
Reg = registration; Rand = randomization; ECOG = Eastern Cooperative Oncology Group; AST = aspartate aminotransferase; ALT = alanine ami-
notransferase; FACT-F = Functional Assessment of Cancer Therapy, Fatigue subscale; SF-36 = Short Form 36.COURNEYA et al.
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4. CONCLUSIONS
In various populations, both healthy and with a disease,
PA has been associated with numerous health benefits.
As yet, no conclusive evidence has been found that PA
will reduce the likelihood of colon cancer recurrence
or will extend survival. Our study has the potential to
answer this question definitively and will provide valu-
able insights into this association regardless of the fi-
nal results of the trial. In addition, the study will obtain
robust data about the effect of PA on important second-
ary endpoints in colon cancer survivors including qual-
ity of life, fatigue, mood, biologic correlative measures,
and cost-effectiveness.
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